Literature DB >> 20045400

Effects of anti-CD70 mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease.

Satoshi Yanagisawa1, Naoya Takeichi, Tomoki Kaneyama, Hideo Yagita, Syun'ichiro Taniguchi, Byung S Kim, Chang-Sung Koh.   

Abstract

Ligation of CD27, a member of the tumor necrosis factor (TNF) receptor family, by its ligand CD70 is thought to be important in T cell activation, expansion and survival, B cell activation, and NK cell activation. We examined the role of CD70 in Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) mice. Blocking of CD70 in effector phase by anti-CD70 monoclonal antibody (mAb) suppressed the development of TMEV-IDD. The number of IFN-gamma- or TNF-alpha-producing cells in the spleen and mRNA levels of IFN-gamma and TNF-alpha in spinal cord were decreased in mice treated with anti-CD70 mAb at the effector phase. In contrast, treatment with anti-CD70 mAb in induction phase failed to reduce these responses, compared to nonspecific IgG-treated control mice. These data suggest that CD70 is critically involved in the pathogenesis of TMEV-IDD and that antibodies against CD70 could be a novel therapeutic approach in the clinical treatment of demyelinating diseases such as human multiple sclerosis. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20045400     DOI: 10.1016/j.brainres.2009.12.058

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

Review 1.  TNF superfamily in inflammatory disease: translating basic insights.

Authors:  Michael Croft; Wei Duan; Heonsik Choi; So-Young Eun; Shravan Madireddi; Amit Mehta
Journal:  Trends Immunol       Date:  2011-12-13       Impact factor: 16.687

2.  CD70: probably being a therapeutic target in human multiple sclerosis.

Authors:  Xu Wangdong
Journal:  Rheumatol Int       Date:  2011-12-08       Impact factor: 2.631

Review 3.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.